Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Randomized, Double-blind, Placebo-controlled Trial (1-BETTER) Examining XB2001 (Anti-IL-1⍺ True Human Antibody) in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

NCT04825288 is registered in ClinicalTrials.gov with XBiotech, Inc. as lead sponsor.

NCT NCT04825288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04825288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Randomized, Double-blind, Placebo-controlled Trial (1-BETTER) Examining XB2001 (Anti-IL-1⍺ True Human Antibody) in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
Lead sponsor
XBiotech, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 27, 2021
Completion date
June 10, 2025
Enrollment
76 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer